Abstract
Studies have suggested that abnormal expression of complement regulatory proteins and cytokines contribute significantly to the path-physiology of rheumatoid arthritis. In this context, Decay accelerating factor (DAF) a complement regulatory protein is gaining increased attention. With the notion that immune effecter mechanisms are all interlinked and circulating peripheral blood mononuclear cells (PBMCs) should have a role in a systemic disease like rheumatoid arthritis, we studied the modulation and significance of PBMC-DAF and cytokines in RA. Seventy-five RA patients and 75 healthy controls were recruited. Expression of DAF and cytokines (IFN-γ, IL-17A and IL-10) in the PBMCs of patients and controls was determined. Correlations among DAF, cytokines, and disease activity were evaluated by standard statistical methods. The effect of IFN-γ, IL-17A, and IL-10 on the expression of DAF in patients and controls was studied in vitro. Expression of PBMC-DAF declined in patients both at mRNA and surface level and correlated negatively with the disease activity. Expression of IFN-γ also declined in patients but correlated positively with DAF and negatively with disease activity. Expression of IL-17A and IL-10 was higher in patients. The levels correlated positively with disease activity and negatively with DAF both in patients and controls. In vitro studies indicated that IFN-γ up-regulated DAF expression in PBMCs, whereas IL-17A and IL-10 had negative effect on the same. The decline in the PBMC-DAF is a contributing factor in manifestations of RA. Cytokine environment contributes to this decline. These findings brought novel insights into the complement-cytokine axis in the path-physiology of RA.
Similar content being viewed by others
References
Kvien TK, Uhlig T, Ødegard S, Heiberg MS (2006) Epidemiological aspects of rheumatoid arthritis: the sex ratio. Ann N Y Acad Sci 1069:212–222
Ricklin D, Lambris JD (2013) Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol 190:3831–3838
Kim DD, Song WC (2006) Membrane complement regulatory proteins. Clin Immunol 118:127–136
Zipfel P, Skerka C (2009) Complement regulators and inhibitory proteins. Nat Rev Immunol 9:729–740
Williams AS, Mizuno M, Richards PJ, Holt DS, Morgan BP (2004) Deletion of the gene encoding CD59a in mice increases disease severity in a murine model of rheumatoid arthritis. Arthritis Rheum 50:3035–3044
Arora V, Verma J, Dutta R, Marwah V, Kumar A, Das N (2004) Reduced complement receptor 1 (CR1, CD35) transcription in systemic lupus erythematosus. Mol Immunol 41:449–456
Biswas B, Kumar U, Das N (2012) Expression and significance of leukocyte membrane cofactor protein transcript in systemic lupus erythematosus. Lupus 21:517–525
Medof ME, Walter EI, Rutgers JL, Knowles DM, Nussenzweig V (1987) Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J Exp Med 165:848–864
Capasso M, Durrant LG, Stacey M, Gordon S, Ramage J, Spendlove l (2006) Co stimulation via CD55 on human CD4 + T cells mediated by CD97. J Immunol 177:1070–1077
Heeger PS, Lalli PN, Lin F, Valujskikh A, Liu J, Muqim N et al (2005) Decay accelerating factor modulates induction of T cell immunity. J Exp Med 201:1523–1530
Miwa T, Maldonado MA, Zhou L, Sun X, Luo HY, Cai D et al (2002) Deletion of decay-accelerating factor (CD55) exacerbates auto-immune disease development in MRL/lpr mice. Am J Pathol 161:1077–1086
Toomey CB, Cauvi DM, Pollard KM (2014) The role of decay accelerating factor in environmentally induced and idiopathic systemic autoimmune disease. Autoimmune Dis 452853:12. doi:10.1155/2014/452853
Hoek RM, de Launay D, Kop EN, Yilmaz-Elis AS, Lin F, Reedquist KA et al (2010) Deletion of either CD55 or CD97 ameliorates arthritis in mouse models. Arthritis Rheum 62:1036–1042
Karpus ON, Kiener HP, Niederreiter B, Yilmaz-Elis AS, van der Kaa J, Ramaglia V et al (2015) CD55 deposited on synovial collagen fibers protects from immune complex-mediated arthritis. Arthritis Res Ther 17:6. doi:10.1186/s13075-015-0518-4
Jones J, Laffafian I, Cooper AM, Williams BD, Morgan BP (1994) Expression of complement regulatory molecules and other surface markers on neutrophils from synovial fluid and blood of patients with rheumatoid arthritis. Br J Rheumatol 33:707–712
Arora M, Kumar A, Das SN, Srivastava LM (1998) Complement-regulatory protein expression and activation of complement cascade on erythrocytes from patients with rheumatoid arthritis (RA). Clin Exp Immunol 111:102–106
Fattouh M, Mohamed T, A Fadl ME, Hafez AR (2013) A flowcytometry study of complement regulatory proteins expression on peripheral blood cells in rheumatoid arthritis patients. J Am Sci 9:193–201
Edwards CK, Green JS, Volk HD, Schiff M, Kotzin BL, Mitsuya H et al (2012) Combined anti-tumor necrosis factor-α therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy alone. Front Immunol 3:366–370
Bucht A, Larsson P, Weisbrot L, Thorne C, Pisa P, Smedegård G, Keystone EC, Grönberg A (1996) Expression of interferon-gamma (IFN-gamma), IL-10, IL-12 and transforming growth factor-beta (TGF-beta) mRNA in synovial fluid cells from patients in the early and late phases of rheumatoid arthritis (RA). Clin Exp Immunol 103:357–367
Tukaj S, Kotlarz A, Jozwik A, Smolenska Z, Bryl E, Witkowski JM et al (2010) Cytokines of the Th1 and Th2 type in sera of rheumatoid arthritis patients; correlations with anti-Hsp40 immune response and diagnostic markers. Acta Biochim Pol 57:327–332
Milman N, Karsh J, Booth RA (2010) Correlation of a multi-cytokine panel with clinical disease activity in patients with rheumatoid arthritis. Clin Biochem 43:1309–1314
Lee J, Lee J, Park M-K, Lim MA, Park EM (2013) Interferon gamma suppresses collagen-induced arthritis by regulation of Th17 through the induction of indoleamine-2, 3-deoxygenase. PLoS ONE 8:e60900
Doodes PD, Cao Y, Hamel KM, Wang Y, Farkas B, Iwakura Y, Finnegan A (2008) Development of proteoglycan-induced arthritis is independent of IL-17. J Immunol 181:329–337
Choy Ernest (2012) Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology 51:v3–v11
Kellner H (2013) Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential. Ther Adv Musculoskelet Dis 5:141–152
Saraiva M, O’Garra A (2010) The regulation of IL-10 production by immune cells. Nat Rev Immunol 10:170–181
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324
Schulze-Koops H, Lipsky PE, Kavanaugh AF, Davis LS (1996) Persistent reduction in IL-6 mRNA in peripheral blood mononuclear cells of patients with rheumatoid arthritis after treatment with a monoclonal antibody to CD54 (ICAM-1). Clin Exp Immunol 106:190–196
Arora V, Mondal AM, Grover R, Kumar A, Chattopadhyay P, Das N (2007) Modulation of CR1 transcript in systemic lupus erythematosus (SLE) by IFN-gamma and immune complex. Mol Immunol 44(7):1722–1728
Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR et al (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59:762–784
Piccoli AK, Alegretti AP, Schneider L, Lora PS, Xavier RM (2011) Expression of complement regulatory proteins CD55, CD59, CD35, and CD46 in rheumatoid arthritis. Rev Bras Reumatol 51:503–510
Davies ME, Horner A, Loveland BE, McKenzie IF (1994) Upregulation of complement regulators MCP (CD46), DAF (CD55) and protectin (CD59) in arthritic joint disease. Scand J Rheumatol 23:316–321
Harris CL, Williams AS, Linton SM, Morgan BP (2002) Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half -life in vivo. Clin Exp Immunol 129:198–207
Smolen JS, Breedveld FC, Eberl G, Jones I, Leeming M, Wylie GL et al (1995) Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum 38:38–43
Nydegger UE, Zubler RH, Gabay R, Joliat G, Karagevrekis CH, Lambert PH, Miescher PA (1977) Circulating complement breakdown products in patients with rheumatoid arthritis. Correlation between plasma C3d, circulating immune complexes, and clinical activity. J Clin Invest 59:862–868
Mallya RK, Vergani D, Tee DE, Bevis L, de Beer FC, Berry H, Hamilton ED, Mace BE, Pepys MB (1982) Correlation in rheumatoid arthritis of concentrations of plasma C3d, serum rheumatoid factor, immune complexes and C-reactive protein with each other and with clinical features of disease activity. Clin Exp Immunol 48:747–753
Makinde VA, Senaldi G, Jawad AS, Berry H, Vergani D (1989) Reflection of disease activity in rheumatoid arthritis by indices of activation of the classical complement pathway. Ann Rheum Dis 48:302–306
Corvetta A, Pomponio G, Rinaldi N, Luchetti MM, Di Loreto C, Stramazzotti D (1992) Terminal complement complex in synovial tissue from patients affected by rheumatoid arthritis, osteoarthritis and acute joint trauma. Clin Exp Rheumatol 10:433–438
Konttinen YT, Ceponis A, Meri S, Vuorikoski A, Kortekangas P, Sorsa T, Sukura A, Santavirta S (1996) Complement in acute and chronic arthritides: assessment of C3c, C9, and protectin (CD59) in synovial membrane. Ann Rheum Dis 55:888–894
Sanders ME, Kopicky JA, Wigley FM, Shin ML, Frank MM, Joiner KA (1986) Membrane attack complex of complement in rheumatoid synovial tissue demonstrated by immunofluorescent microscopy. J Rheumatol 13:1028–1034
Nasu J, Mizuno M, Uesu T, Takeuchi K, Inaba T et al (1998) Cytokine-stimulated release of decay-accelerating factor (DAF; CD55) from HT-29 human intestinal epithelial cells. Clin Exp Immunol 113:379–385
Das N, Biswas B, Arora V, Kumar U, Kumar A (2013) Effect of immune complexes and cytokines on expression and modulation of neutrophil complement regulatory proteins in SLE. Frontiers Immunol. Suppl doi: 10.3389/conf.fimmu.2013.02.00208
Suzuki H, Lasbury ME, Fan L, Vittal R, Mickler EA et al (2013) Role of complement activation in obliterative bronchiolitis post-lung transplantation. J Immunol 191:4431–4439
Cocuzzi ET, Bardenstein DS, Stavitsky A, Sundarraj N, Medof ME (2001) Upregulation of DAF (CD55) on orbital fibroblasts by cytokines. Differential effects of TNF-beta and TNF-alpha. Curr Eye Res 23:86–92
Du Y, Deng L, Li Y, Gan L, Wang Y, Shi G (2013) Decreased PERP expression on peripheral blood mononuclear cells from patient with rheumatoid arthritis negatively correlates with disease activity. Clin Dev Immunol. doi:10.1155/2013/256462
Alanara T, Karstila K, Moilanen T, Silvennoinen O, Isomaki P (2010) Expression of IL-10 family cytokines in rheumatoid arthritis elevated levels of IL-19 in the joints. Scand J Rheumatol 39:118–126
Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird PA, Lee CS, Shnier R, Portek IJ (2006) Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 54:1122–1131
Meyer PW, Hodkinson B, Ally M, Musenge E, Wadee AA, Fickl H, Tikly M, Anderson R (2010) Circulating cytokine profiles and their relationships with autoantibodies, acute phase reactants, and disease activity in patients with rheumatoid arthritis. Mediators Inflamm 2010:154–158
Paradowska-Gorycka A, Trefler J, Maciejewska-Stelmach J, Cki JKL (2010) Interleukin-10 gene promoter polymorphism in Polish rheumatoid arthritis patients. Int J Immunogenet 37:225–231
Van Weyenbergh J, Lipinski P, Abadie A et al (1998) Antagonistic action of IFN-α, IFN-g on high affinity Fcg receptor expression in healthy controls and multiple sclerosis patients. J Immunol 161:1568–1574
Schoenborn JR, Wilson CB (2007) Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 96:41–101
Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich JM, Jack RS, Wunderlich FT et al (2011) Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity 34:566–578
Acknowledgments
The authors are grateful to University Grants Commission (UGC), New Delhi, for financial support. We are thankful to all the volunteers of the patient and control groups for their participation in this study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that there is no conflict of interest.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Pahwa, R., Kumar, U. & Das, N. Modulation of PBMC-decay accelerating factor (PBMC-DAF) and cytokines in rheumatoid arthritis. Mol Cell Biochem 414, 85–94 (2016). https://doi.org/10.1007/s11010-016-2661-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11010-016-2661-x